Compositions useful for the treatment of immune-related diseases
The present invention relates to a gingival fibroblast-derived product for use in the treatment or prevention of an immune-related disease in an individual.
1. A method for treating an immune-related disease in an individual in need thereof, wherein the disease is selected from the group consisting of an allergy, an inflammatory skin disease and asthma, comprising administering to the individual a therapeutically effective amount of a gingival fibroblast-derived product.
2. The method of claim 1 , wherein the inflammatory skin disease is atopic dermatitis.
3. The method of claim 1 , wherein the gingival fibroblast-derived product is selected from the group consisting of gingival fibroblast whole cells, a gingival fibroblast culture, a gingival fibroblast extract and a gingival fibroblast conditioned medium.
4. The method of claim 1 , wherein the gingival fibroblast-derived product is obtained from gingival fibroblasts taken from the individual.
5. The method of claim 1 , comprising:
taking gingival fibroblasts from the individual;
culturing the gingival fibroblasts;
obtaining a gingival fibroblast-derived product from the cultured gingival fibroblasts;
administering the gingival fibroblast-derived product to the individual.
6. The method of claim 1 , wherein the gingival fibroblast-derived product is associated with at least one agent intended for the treatment of inflammatory skin disease.
7. The method of claim 1 , wherein the gingival fibroblast-derived product is associated with at least one agent intended for the treatment of inflammatory skin disease selected from the group consisting of a corticosteroid, a calcineurin inhibitor, an emollient, a moisturizer.
8. The method of claim 1 , wherein the gingival fibroblast-derived product is administered topically.
9. A method for treating an immune-related disease in an individual in need thereof, wherein the disease is selected from the group consisting of an allergy, an inflammatory skin disease and asthma, comprising administering to the individual a therapeutically effective amount of a composition comprising a gingival fibroblast-derived product, and comprising at least one agent intended for the treatment of an inflammatory skin disease, and comprising at least one pharmaceutically acceptable carrier or excipient.